Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
NCT03822884Phase 1Completed
- Sponsor
- Biosidus
- Start
- Sep 2016
- Primary completion
- Sep 2016
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 1, randomised, open-label trial of epoetin alpha in anemia, sponsored by Biosidus. Primary endpoints: Area Under the Serum Concentration-Time Curve from Time 0 to 120 Hours, Area Under the Serum Concentration-Time Curve from Time 0 Extrapolated to Infinity at 120 hours and 2 more. Started Sep 2016; status: completed.
02
Drugs
epoetin alpha
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03822884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822884.